CA3198795A1 - Complexing agent salt formulations of pharmaceutical compounds - Google Patents
Complexing agent salt formulations of pharmaceutical compoundsInfo
- Publication number
- CA3198795A1 CA3198795A1 CA3198795A CA3198795A CA3198795A1 CA 3198795 A1 CA3198795 A1 CA 3198795A1 CA 3198795 A CA3198795 A CA 3198795A CA 3198795 A CA3198795 A CA 3198795A CA 3198795 A1 CA3198795 A1 CA 3198795A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical compound
- compound
- pharmaceutical
- complexing agent
- mosm
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063115451P | 2020-11-18 | 2020-11-18 | |
| US202063115453P | 2020-11-18 | 2020-11-18 | |
| US202063115458P | 2020-11-18 | 2020-11-18 | |
| US202063115445P | 2020-11-18 | 2020-11-18 | |
| US63/115,451 | 2020-11-18 | ||
| US63/115,458 | 2020-11-18 | ||
| US63/115,445 | 2020-11-18 | ||
| US63/115,453 | 2020-11-18 | ||
| PCT/US2021/059760 WO2022109050A1 (en) | 2020-11-18 | 2021-11-17 | Complexing agent salt formulations of pharmaceutical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3198795A1 true CA3198795A1 (en) | 2022-05-27 |
Family
ID=81709677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3198795A Pending CA3198795A1 (en) | 2020-11-18 | 2021-11-17 | Complexing agent salt formulations of pharmaceutical compounds |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US11534454B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4247340A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023551145A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3198795A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022109050A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3968979B1 (en) | 2019-05-15 | 2026-07-01 | Bexson Biomedical, Inc. | KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| EP4161503A4 (en) | 2020-06-08 | 2024-07-03 | Tactogen Inc. | Advantageous benzofuran compositions for mental disorders or enhancement |
| TW202216676A (zh) | 2020-07-06 | 2022-05-01 | 美商塔朵根公司 | 用於心理疾病或心理強化的有益苯并噻吩組合物 |
| AU2021322291A1 (en) | 2020-08-06 | 2023-04-06 | Tactogen Inc | 2-aminoindane compounds for mental disorders or enhancement |
| EP4247340A4 (en) | 2020-11-18 | 2024-10-02 | Bexson Biomedical, Inc. | COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS |
| WO2022204323A1 (en) * | 2021-03-24 | 2022-09-29 | The Trustees Of Columbia University In The City Of New York | Non-hallucinogenic ariadne analogs for treatment of neurological and psychiatric disorders |
| KR20240013170A (ko) | 2021-05-25 | 2024-01-30 | 아타이 테라퓨틱스, 인크. | 신규 n,n-디메틸트립타민 염 및 결정질 염 형태 |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| EP4525916A4 (en) * | 2022-05-18 | 2026-05-20 | Bexson Biomedical Inc | LOW STOICHIOMETRIC RATIO SALT FORMULATIONS FOR COMPLEXING AGENTS OF PHARMACEUTICAL COMPOUNDS |
| IN202221054235A (cg-RX-API-DMAC7.html) | 2022-09-22 | 2023-11-03 | ||
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| EP4431083A1 (en) * | 2023-03-16 | 2024-09-18 | Adalvo Limited | Formulation of dalbavancin |
| AU2024284688A1 (en) * | 2023-06-06 | 2025-12-11 | Transcend Therapeutics, Inc. | Psychoactive medicines and their use for treating psychiatric and neurological conditions and disorders |
| CN116769070B (zh) * | 2023-06-07 | 2025-07-01 | 浙江工业大学 | 一种功能化磁性纳米颗粒及作为手性萃取剂在液-液萃取拆分手性化合物中的应用 |
| EP4773958A1 (en) * | 2023-09-08 | 2026-07-15 | ATAI Therapeutics, Inc. | Parenteral formulations for n,n-dimethyltryptamine (dmt) and dmt analogs, methods of making, and methods of use thereof |
| WO2025111482A1 (en) * | 2023-11-22 | 2025-05-30 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4911920A (en) | 1986-07-30 | 1990-03-27 | Alcon Laboratories, Inc. | Sustained release, comfort formulation for glaucoma therapy |
| FR2588189B1 (fr) | 1985-10-03 | 1988-12-02 | Merck Sharp & Dohme | Composition pharmaceutique de type a transition de phase liquide-gel |
| DK0495421T3 (da) | 1991-01-15 | 1996-12-09 | Alcon Lab Inc | Anvendelse af carragenaner i topiske ophthalmiske sammensætninger |
| US5212162A (en) | 1991-03-27 | 1993-05-18 | Alcon Laboratories, Inc. | Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5352683A (en) | 1993-03-05 | 1994-10-04 | Virginia Commonwealth University Medical College Of Virginia | Method for the treatment of chronic pain |
| SE501482C2 (sv) | 1993-06-24 | 1995-02-27 | Leiras Oy | Komposition för topisk administration av bispilokarpinsyradiestrar till ögat i form av en vattenlösning |
| JP3283713B2 (ja) * | 1993-12-06 | 2002-05-20 | 武田薬品工業株式会社 | 水溶性の改善された水不溶性ないし難溶性化合物含有組成物 |
| DE69425948T2 (de) * | 1993-12-06 | 2001-02-22 | Takeda Chemical Industries, Ltd. | Zusammensetzung mit verbesserter Wasserlöslichkeit, enthaltend eine Wasserunlösliche oder an Wasser schwerunlösliche Verbindung |
| ES2210769T3 (es) | 1997-06-13 | 2004-07-01 | Cydex Inc. | Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua. |
| ES2257795T3 (es) | 1997-07-01 | 2006-08-01 | Pfizer Products Inc. | Procedimiento para producir una ciclodextrina. |
| US6699849B1 (en) | 1998-02-23 | 2004-03-02 | Cyclops, Ehf. | Cyclodextrin complexes of benzodiazepines |
| IT1303735B1 (it) * | 1998-11-11 | 2001-02-23 | Falorni Italia Farmaceutici S | Acidi ialuronici reticolati e loro usi medici. |
| CN1172908C (zh) | 1999-12-10 | 2004-10-27 | 中国科学院上海药物研究所 | N-取代苄基或苯基芳香磺酰胺化合物及其用途 |
| US6348777B1 (en) | 2000-02-29 | 2002-02-19 | Alaris Medical Systems, Inc. | Power management system |
| EP1383445A4 (en) | 2001-03-20 | 2005-04-13 | Cydex Inc | FORMULATIONS WITH PROPOFOL AND A SULFOALKYL ETHER CYCLODEXTRIN |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| US6869939B2 (en) | 2002-05-04 | 2005-03-22 | Cydex, Inc. | Formulations containing amiodarone and sulfoalkyl ether cyclodextrin |
| NZ537995A (en) * | 2002-08-20 | 2007-11-30 | Bristol Myers Squibb Co | Inclusion complex of aripiprazole in a substituted b-cyclodextrin |
| AU2004260884B2 (en) | 2003-07-22 | 2009-11-19 | Crucell Holland B.V. | Binding molecules against SARS-coronavirus and uses thereof |
| KR20060115350A (ko) * | 2003-09-02 | 2006-11-08 | 화이자 프로덕츠 인크. | 지프라시돈의 지속 방출형 투여 형태 |
| KR20060113737A (ko) | 2003-12-22 | 2006-11-02 | 쉐링 코포레이션 | 약제학적 조성물 |
| DE102005041860A1 (de) * | 2005-09-02 | 2007-03-08 | Schering Ag | Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen |
| CN1939298A (zh) | 2005-09-29 | 2007-04-04 | 中国科学院上海药物研究所 | 硫酸舒欣啶固体和靶向制剂及其制备方法 |
| KR20080080087A (ko) * | 2005-09-30 | 2008-09-02 | 티티아이 엘뷰 가부시키가이샤 | 신규 약학 담체를 이용한 경피 약물 전달시스템, 장치 및방법 |
| JP2009530385A (ja) | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| CA2698038A1 (en) | 2007-07-26 | 2009-01-29 | Entra Pharmaceuticals Inc. | Systems and methods for delivering drugs |
| US8492538B1 (en) * | 2009-06-04 | 2013-07-23 | Jose R. Matos | Cyclodextrin derivative salts |
| JP5785175B2 (ja) * | 2009-10-26 | 2015-09-24 | 石葯集団中奇制葯技▲術▼(石家庄)有限公司 | スルホブチルエーテルシクロデキストリン塩を含有する内水相を有するリポソーム |
| US20120295893A1 (en) | 2009-12-14 | 2012-11-22 | Coeruleus Ltd. | Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs |
| ITRM20100630A1 (it) | 2010-12-03 | 2012-06-04 | Dyepower | Procedimento di sintesi di complessi precursori e sensibilizzatori del biossido di titanio basati su complessi polipiridinici di rutenio. |
| EP2653479B1 (en) | 2010-12-16 | 2015-12-02 | Sumitomo Seika Chemicals Co. Ltd. | Method for producing pseudopolyrotaxane aqueous dispersion |
| AU2012221704B2 (en) | 2011-02-23 | 2013-12-05 | Coeruleus Ltd. | Flumazenil complexes, compositions comprising same and uses thereof |
| JP6296985B2 (ja) | 2011-10-14 | 2018-03-20 | ザ ユナイテッド ステイツ オブ アメリカ, アズ リプレゼンテッド バイ ザ セクレタリー, デパートメント オブ ヘルス アンド ヒューマン サービシーズ | うつ病及び神経障害性疼痛の治療における(2r,6r)−ヒドロキシノルケタミン、(s)−デヒドロノルケタミン及び他の(r,s)−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用 |
| JP2015512418A (ja) | 2012-03-30 | 2015-04-27 | ザ ジェネラル ホスピタル コーポレイション | うつ病の治療におけるスコポラミンおよびケタミンを含む組成物 |
| US20130296437A1 (en) | 2012-05-04 | 2013-11-07 | E-Therapeutics Plc | Treatment of Depression |
| CN104520326A (zh) | 2012-06-21 | 2015-04-15 | Ucb医药有限公司 | 药物制剂 |
| US10124940B2 (en) | 2012-09-11 | 2018-11-13 | Zolo Solutions, Inc. | Systems, methods, and devices for dispensing one or more substances |
| WO2014121235A2 (en) | 2013-02-01 | 2014-08-07 | Zoneone Pharma, Inc. | Transformation of drug cyclodextrin complex compositions into compositions of mixtures of lipid vesicle encapsulated drug and cyclodextrin drug complexes |
| US9446186B2 (en) | 2013-03-01 | 2016-09-20 | Bigfoot Biomedical, Inc. | Operating an infusion pump system |
| CN105437676B (zh) | 2014-08-14 | 2020-03-24 | 上海利统生化制品有限公司 | 用于阻碍植物乙烯反应的层合物及其制备方法 |
| FR3032353B1 (fr) | 2015-02-06 | 2017-03-10 | Jacques Seguin | Composition pharmaceutique et dispositif pour le traitement de la douleur |
| CN108601891B (zh) | 2016-01-12 | 2022-05-13 | 输液创新有限公司 | 输注设备 |
| AU2017250086A1 (en) | 2016-04-11 | 2018-09-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| WO2017218918A1 (en) * | 2016-06-17 | 2017-12-21 | Ys Pharmtech | Stabilization of epinephrine formulations |
| DE102016014603A1 (de) * | 2016-06-30 | 2018-01-04 | Thomas Herkenroth | Synthetisches Ayahuasca |
| SG11201901147TA (en) | 2016-08-25 | 2019-03-28 | Validose Inc | System and method for controlled medical therapy |
| BR102017016440A2 (pt) * | 2017-07-31 | 2019-03-19 | Universidade Federal Do Rio Grande Do Sul | Composição para terapia gênica do sistema nervoso central, processo de obtenção e uso da mesma |
| EP3498266A1 (en) | 2017-12-15 | 2019-06-19 | Bayer Consumer Care AG | Formulations of copanlisib |
| US20200384188A1 (en) | 2017-11-14 | 2020-12-10 | Bexson Biomedical, Inc. | Systems, devices, formulations and methods for controlled drug delivery |
| CN111330019B (zh) | 2018-12-18 | 2022-03-15 | 中国人民解放军第二军医大学 | 氟马西尼包合物及其制备方法和应用 |
| EP3968979B1 (en) | 2019-05-15 | 2026-07-01 | Bexson Biomedical, Inc. | KETAMINE FORMULATION FOR SUBCUTANEOUS INJECTION |
| US12576026B2 (en) | 2020-07-08 | 2026-03-17 | Extrovis Ag | Formulations of nebivolol |
| EP4247340A4 (en) | 2020-11-18 | 2024-10-02 | Bexson Biomedical, Inc. | COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS |
| EP4247386A4 (en) * | 2020-11-18 | 2024-12-18 | Bexson Biomedical, Inc. | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS |
| EP4525916A4 (en) | 2022-05-18 | 2026-05-20 | Bexson Biomedical Inc | LOW STOICHIOMETRIC RATIO SALT FORMULATIONS FOR COMPLEXING AGENTS OF PHARMACEUTICAL COMPOUNDS |
| WO2025111482A1 (en) | 2023-11-22 | 2025-05-30 | Bexson Biomedical, Inc. | Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios |
-
2021
- 2021-11-17 EP EP21895527.6A patent/EP4247340A4/en active Pending
- 2021-11-17 JP JP2023529879A patent/JP2023551145A/ja active Pending
- 2021-11-17 CA CA3198795A patent/CA3198795A1/en active Pending
- 2021-11-17 WO PCT/US2021/059760 patent/WO2022109050A1/en not_active Ceased
- 2021-12-09 US US17/546,880 patent/US11534454B2/en active Active
-
2022
- 2022-11-04 US US17/981,348 patent/US12472201B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023551145A (ja) | 2023-12-07 |
| US20230124101A1 (en) | 2023-04-20 |
| EP4247340A4 (en) | 2024-10-02 |
| US12472201B2 (en) | 2025-11-18 |
| WO2022109050A1 (en) | 2022-05-27 |
| US11534454B2 (en) | 2022-12-27 |
| US20220152088A1 (en) | 2022-05-19 |
| EP4247340A1 (en) | 2023-09-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12472201B2 (en) | Complexing agent salt formulations of pharmaceutical compounds | |
| US10973780B2 (en) | Ketamine formulation for subcutaneous injection | |
| EP2773379B1 (en) | Subcutaneous delivery of polymer conjugates of therapeutic agents | |
| ES2610966T3 (es) | Formulaciones que comprenden 2-amino-2-[2-(4-octil-fenil)-etil]-propano-1,3-diol | |
| US9375483B2 (en) | Stable liquid pharmaceutical composition containing piroxicam or its pharmaceutically acceptable salt and hyaluronic acid or its pharmaceutically acceptable salt and the manufacturing method thereof | |
| US20100010059A1 (en) | Anticancer oral formulation | |
| BR112021000658A2 (pt) | Dendrímero, composições, composição farmacêutica, método de tratamento de câncer, uso de dendrímero, método, uso, dendrímero ou composição, processo de produção de dendrímero e intermediários para a produção de dendrímero | |
| US20250345458A1 (en) | Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios | |
| WO2025111482A1 (en) | Complexing agent salt formulations of pharmaceutical compounds at low stoichiometric ratios | |
| US20230405018A1 (en) | Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators | |
| EP2934593B1 (en) | Cabazitaxel composition | |
| US20260014191A1 (en) | Complexing agent salt formulations of pharmaceutical compounds | |
| AU2017242544A1 (en) | Cyclodextrin-panobinostat adduct | |
| CN101665449B (zh) | 他米巴罗汀的水溶性前药及其制备方法与应用 | |
| CN114558004B (zh) | Qtx125药物制剂 | |
| KR20140138640A (ko) | 비강내 졸피뎀 투여용 치료 조성물 | |
| JP2025520542A (ja) | アポモルヒネプロドラッグおよびその使用 | |
| HK40066455A (en) | Qtx125 drug formulations | |
| HK40066455B (en) | Qtx125 drug formulations | |
| JP2024511597A (ja) | シロシビンの類似体、塩、組成物、及び使用方法 | |
| WO2006095844A1 (ja) | 医薬製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241108 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241108 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251107 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251107 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20251117 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20251117 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251117 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260112 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260112 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260112 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260122 |